For the year ending 2025-12-31, CTRVP had $1,421,654 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Effect of exchange rates on cash | 0 |
| Depreciation | 0 |
| Amortization of debt discount | 0 |
| Inducement expense | 0 |
| Write-off related party note receivable | 0 |
| Change in fair value of contingent consideration | 0 |
| Right of use asset | 0 |
| Operating lease liability | 0 |
| Stock-based compensation | 20,783 |
| Change in fair value of derivative instrument-warrants | 4,089,753 |
| Accounts payable and accrued expenses | 1,431 |
| Prepaid expenses and other assets | -491,617 |
| Asset impairment loss | 402,746 |
| Net loss | -8,277,850 |
| Net cash used in operating activities | -3,271,520 |
| Investment in related party receivable | 0 |
| Investment in license agreement | 132,117 |
| Net cash used in investing activities | -132,117 |
| Proceeds from equity and debt issuance under spa, net of discount | 0 |
| Proceeds from the issuance of common stock and warrants, net | 9,000,000 |
| Equity issuance costs | 802,597 |
| Payments on notes payable | 3,372,112 |
| Net cash (used in) provided by financing activities | 4,825,291 |
| Net increase (decrease) in cash | 1,421,654 |
| Investment in related party receivable | 0 |
| Effect of exchange rates on cash | 0 |
| Investment in license agreement | 132,117 |
| Net cash used in investing activities | -132,117 |
| Net increase (decrease) in cash | 1,421,654 |
| Cash at beginning of period | 406,408 |
| Cash at end of period | 1,828,062 |
Hepion Pharmaceuticals, Inc. (CTRVP)
Hepion Pharmaceuticals, Inc. (CTRVP)